TRML 8-K: Press Release Furnished for Quarter Ended June 30, 2025

Rhea-AI Filing Summary

Tourmaline Bio, Inc. furnished a Current Report on Form 8-K stating it issued a press release announcing business highlights and financial results for the quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104. The company states this information is being furnished, not filed, so it is not subject to Section 18 liabilities and is not incorporated by reference into other filings unless expressly stated.

The 8-K contains no numerical financial data or operational detail itself; readers must consult Exhibit 99.1 for the actual figures and narrative. The registrant's common stock trades under TRML on the Nasdaq Global Select Market and no other material transactions or financial tables are included in this filing.

Insights

Financial Analyst

TL;DR: The 8-K notifies investors a press release with Q2 2025 results was furnished; the filing itself provides no financial detail to evaluate performance.

The filing is a routine disclosure that alerts the market a press release exists with business highlights and quarter-end results. Because the 8-K does not include revenue, earnings, cash flow, or guidance, there is insufficient information here to assess financial performance or trend direction. The explicit statement that the material is "furnished, not filed" limits legal exposure and signals readers must review Exhibit 99.1 and the Inline XBRL cover for substantive numbers and disclosures.

Corporate Governance Expert

TL;DR: Procedurally standard: company furnished a press release and noted it is not incorporated by reference; no governance or material control signals present.

This 8-K follows common practice by furnishing a press release and attaching an XBRL cover. The filing emphasizes the distinction between "furnished" and "filed," which is important for liability and incorporation-by-reference considerations. There are no disclosures here about executive changes, related-party transactions, or material agreements, so from a governance perspective the document is neutral and administrative rather than indicative of corporate control or structural changes.

FALSE000182750600018275062025-08-132025-08-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 13, 2025

___________________________________

TOURMALINE BIO, INC.

(Exact name of registrant as specified in its charter)

___________________________________

Delaware (State or other jurisdiction of incorporation or organization)

001-40384 (Commission File Number)

83-2377352 (I.R.S. Employer Identification No.)

27 West 24th Street, Suite 702 New York, NY (Address of principal executive offices)

10010 (Zip Code)

Registrant's telephone number, including area code: (646) 481-9832

Not Applicable (Former Name or Former Address, if Changed Since Last Report)

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

TRML

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2025, Tourmaline Bio, Inc. (the “Company”) issued a press release announcing its recent business highlights and financial results for the quarter ended June 30, 2025. A copy of the press release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained in this Item 2.02 and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description
99.1						Press Release dated August 13, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			TOURMALINE BIO, INC.
Date: August 13, 2025			By:			/s/ Ryan Robinson
			Name:			Ryan Robinson
			Title:			Chief Financial Officer

FAQ

What did Tourmaline Bio (TRML) disclose in this 8-K?

The company furnished a press release announcing business highlights and financial results for the quarter ended June 30, 2025, attached as Exhibit 99.1.

Are the financial results in this 8-K filed with the SEC?

No. The company explicitly states the information is furnished, not filed, and therefore is not subject to Section 18 liabilities or automatically incorporated by reference into other filings.

Where can I find the actual financial figures for Q2 2025?

Consult Exhibit 99.1 (the press release) and the attached Inline XBRL cover page (Exhibit 104) included with this 8-K for the financial details.

What is Tourmaline Bio's ticker and exchange?

The registrant's common stock trades under the ticker TRML on the Nasdaq Global Select Market.

Does this filing disclose any material transactions or executive changes?

No. The 8-K does not include financial tables, material transactions, or executive departure/appointment disclosures.